Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Part of paid clinical trials in Anchorage, Alaska.

Sponsor
Incyte Corporation
Study ID
NCT07214779
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • INCB123667 — DRUG
    Oral; tablet
  • Investigator's choice of chemotherapy — DRUG
    The investigator will select the chemotherapy in accordance with the protocol-defined requirements. The possible choices as defined by the protocol:

Study Details

The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.

Key Dates

Start date
Dec 9, 2025
Status verified
May 2026
Primary completion
Nov 15, 2028
Completion
May 14, 2029

Study Design

Enrollment
466 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment Group A (TGA)
    INCB123667 at the protocol-defined dose.
  • Experimental: Treatment Group B (TGB)
    Investigator's choice of chemotherapy at the protocol-defined dose as defined by the protocol.

Primary Outcome Measure

Progression-Free Survival (PFS) by BICR [ Time Frame: Up to 2 years ]

Central Contacts

Locations (29)

FacilityCityStateZIPSite coordinators
Alaska Womens Cancer Care AkwccAnchorageAlaska99508-
City of Hope Medical CenterDuarteCalifornia91010-
University of California, San Diego-Moores Cancer CenterLa JollaCalifornia92037-
Valkyrie Clinical TrialsLos AngelesCalifornia90067-
University of Colorado Cancer CenterAuroraColorado80045-
Georgia Cancer CenterAugustaGeorgia30912-
Carle Cancer CenterEffinghamIllinois62401-2006-
Northshore University Health System-Evanston HospitalEvanstonIllinois60201-
Women'S Cancer CareCovingtonLouisiana70433-
Maine Center For Cancer MedicineScarboroughMaine04074-
Holy Cross HospitalSilver SpringMaryland20910-
Mercy Hospital St. Louis - David C. Pratt Cancer CenterSt LouisMissouri63141-
Billings ClinicBillingsMontana59101-
Center of HopeRenoNevada89511-
Ny Cancer and Blood SpecialistsShirleyNew York11967-
Levine Cancer CenterCharlotteNorth Carolina28204-
Novant Presbyterian HospitalCharlotteNorth Carolina28204-
Atrium Health Wake Forest BaptistWinston-SalemNorth Carolina27157-
Novant Health Oncology SpecialistsWinston-SalemNorth Carolina27103-
Cleveland ClinicClevelandOhio44195-
Oncology Associates of Oregon, P.C.EugeneOregon97401-
Providence Cancer Institute Franz ClinicPortlandOregon97213-
University of Pittsburgh Cancer Institute Cancer ServicesPittsburghPennsylvania15213-
Wellspan Gynecologic OncologyYorkPennsylvania17403-
Sanford Cancer Center-Sioux FallsSioux FallsSouth Dakota57104-8805-
Erlanger Health, Inc.ChattanoogaTennessee37403-
Texas Oncology-AbileneAbileneTexas79606-
Inova Schar Cancer InstituteFairfaxVirginia22031-
Fred Hutchinson Cancer CenterSeattleWashington98109-

Find similar trials in Anchorage, AK

By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Alaska Womens Cancer Care Akwcc· Anchorage, AKCity of Hope Medical Center· Duarte, CAUniversity of California, San Diego-Moores Cancer Center· La Jolla, CAValkyrie Clinical Trials· Los Angeles, CAUniversity of Colorado Cancer Center· Aurora, COGeorgia Cancer Center· Augusta, GA

Related Studies